

BOEHMERT & BOEHMERT P.O.Box 150308 80043 München Germany

Online Filing

Europäisches Patentamt
80298 München

Ihr Zeichen / your ref.
20764639.9

Ihre Nachricht / your letter

Unser Zeichen / our ref.
T75093WOEP

München
19.09.2024

Dr. Ute Kilger
Pettenkoferstraße 22
80336 München
Germany

T +49-89 559680
F +49-89-559685090
kilger@boehmert.de
www.boehmert.de

European Patent Application 20764639.9
THERAPY GUIDANCE AND/OR THERAPY MONITORING
FOR TREATMENT OF SHOCK
4TEEN4 Pharmaceuticals GmbH

On the communication pursuant to Art. 94(3) EPC dated
May 27, 2024:

It is requested to proceed with the examination on the basis of new claims 1 to 18 replacing the claims on file and the remaining documents as currently on file.

I. Amendments

Claims 13, 18 and 20 have been deleted.

Present claim 14 (previous claim 15) has been amended by including a definition of the term “precursor”, based on the disclosure in the paragraphs bridging pages 31 and 32 of the WO publication.

The numbering of the remaining claims and back-references have been adapted to the above amendments as necessary.

No matter going beyond what was in the application documents as filed has been added by the amendment. Thus, all amendments meet the requirements of Art. 123(2) EPC.

BOEHMERT & BOEHMERT Anwaltspartnerschaft mbB • Patentanwälte Rechtsanwälte • AG Bremen-PR 358 HB
München • Bremen • Berlin • Düsseldorf • Frankfurt • Bielefeld • Alicante • Paris • Shanghai

Information about data protection and your rights as data subjects: www.boehmert.com/data-protection
General terms and conditions: www.boehmert.com/termsandconditions

Dr. Ing. Karl Boehmert PA (1899–1973)
Dipl.-Ing. Albert Boehmert PA (1902–1993)
Wilhelm J. H. Stahlberg RA, Bremen
Dr.-Ing. Walter Hoormann PA*, Bremen
Prof. Dr. Heinz Goddar PA*, München, Shanghai
Dr.-Ing. Roland Liesegang PA*, München (1987-2023)
Wolf-Dieter Kuntze RA, Bremen
Dr. Ludwig Kouker RA, Bremen
Dipl.-Ing. Eva Liesegang PA*, München
Dr.-Ing. Matthias Philipp PA*, Bielefeld
Dr. Martin Vitz RA, Düsseldorf, Berlin
Dr. Carl-Richard Haarmann RA, München, Düsseldorf
Dipl.-Phys. Christian W. Appelt PA*, München
Dipl.-Phys. Dr.-Ing. Uwe Manasse PA*, Bremen
Dipl.-Phys. Dr. Thomas L. Bittner PA*, Berlin
Dr. Volker Schmitz-Fohmann, M. JUR. RA, München, Paris
Dipl.-Biochem. Dr. Markus Engelhard PA*, München
Dipl.-Chem. Dr. Karl-Heinz B. Metten PA*, Frankfurt
Dr. Florian Schwab, LL.M. RA, Lic en droit, München
Dr. Andreas Dustmann, LL.M. RA, Berlin, Alicante
Dipl.-Chem. Dr. Volker Scholz PA*, Bremen
Dr. Martin Schaefer RA, Berlin
Dipl.-Phys. Dr. Michael Hartig PA*, München, Paris
Dipl.-Phys. Dr. Steffen Schmidt PA*, München
Dr. Andreas Lucke PA*, München
Dipl.-Chem. Dr. Ute Kilger PA*, Berlin
Malte Nentwig, LL.M. RA, Bremen
Dr. Rudolf Böckenholt, LL.M. RA, Bremen
Peter Groß, LL.M. RA, München, Alicante
Dipl.-Ing. Felix Hermann PA*, München
Dipl.-Phys. Dr. Dennis Kretschmann PA*, München
Dr. Michael Rüberg, LL.M. RA, München, Paris
Dipl.-Phys. Christoph Angerhausen PA*, Düsseldorf
Dipl.-Inform. Dr. Jakob Valvoda PA*, München
Dipl.-Chem. Dr. Martin Erbacher PA*, Bremen
Dr. Daniel Herrmann PA*, Frankfurt, München
Dr. Sebastian Engels RA, Berlin
Silke Freund RA, München
Dipl.-Phys. Dr. Matthias Hofmann PA*, München
Dr. Eckhard Ratjen, LL.M. RA, Bremen
Dipl.-Phys. Dr. Jin Jeon PA*, München
Dr. Mario Araujo** PA*, München
Dipl.-Phys. Dr. Klaus Seranski PA*, Frankfurt, München (2017-2024)
Dipl.-Ing. Oliver Tarvenkorn PA*, Düsseldorf, Bielefeld
Dr. Katrin Seibt RA, Bremen
Dipl.-Biochem. Dr. Sibylla M. Grahm PA*, München
Dipl.-Phys. Dr. Xia Pfaffenzeiler PA*, München
Dipl.-Inform. Fritz Jetzek PA, Bremen
Claudia Deppe RA, München
Dr. Anja Ruge, LL.M. RA, Berlin, München
Mehmet Bengi-Akyürek PA*, München
Dr. Lars Eggersdorfer RA, München
Dipl.-Ing. Simon Cornet PA*, Düsseldorf
Dipl.-Ing. Dr. Sebastian Schlegel PA*, Berlin
Dipl.-Chem. Robert Bernin PA*, Bremen
Dipl.-Ing. Jan Göring PA*, Frankfurt
Dr. Laura Haas, M.Sc. PA*, München
Dr. Hanno Flentje PA*, München
Dr. Lennart-Knud Liefelth PA*, Frankfurt
Dr. Lara Gwinner PA*, München
Dr. Alexander Thamer RA, Berlin
Dr.-Ing. Michael Rübsamen PA*, München
Dipl.-Phys. Dr. Michael Lohse PA*, München
Dr.-Ing. Jonas Boschung, M.Sc., M.Sc. PA*, Düsseldorf
Dipl.-Phys. Dr. Adrian Steffens PA*, Berlin
Melanie Müller RA, Bremen
Dipl.-Phys. Dr. Giulio Schöber PA*, München
Micheline Verwohit RA, München
Nina Rucker RA, München
Dr. Makiko Maruyama*, M.Sc., München
Théodore Ley*, München
Dr. Oleg Lebedev*, Berlin
Fabio Adinolfi RA, München
Dipl.-Chem. Dr. José M. Pfizer PA*, Berlin, München
Malte Windeler, LL.M. oec. RA, Bremen
Dipl.-Ing. Bernhard Jochim PA, Düsseldorf
Dr. Julian Wernicke, LL.M. (UCT) RA, Berlin
Dipl.-Phys. Dr. habil. Daniel Niesner PA*, München
Hannah Eckermann, LL.M. RA, München
Stella Euchner RA, München
Dr. Jan Bohl, M.Sc. PA, Frankfurt
Dr.-Ing. Dominik Denker, M.Sc. PA, Düsseldorf
PA Patentanwalt/Patent Attorney *European Patent Attorney
RA Rechtsanwalt/Attorney at Law (Germany)
** Agente de la Propiedad Industrial (Spain) / Spain)
Vertretung vor dem EUIPO – Marken und Designs
Representation at EUIPO – Trade marks and Designs

II. Clarity

- 1) In section 2.1 of the official communication, it is objected that the term "predetermined threshold" it is not defined.

Applicant respectfully disagrees and submits that it is neither helpful nor justified to limit the claims to specific thresholds or values.

It is common practice for a medical practitioner to choose different thresholds in order to include or exclude patients based on these thresholds. Depending on how the selected thresholds are set, certain numbers of false positive and false negative patients are included. Here, the medical practitioner must weigh the risk in order to decide to which extent the selected threshold values affect the number of false-positive and false-negative patients for a specific medical question.

However, it cannot be excluded that different medical practitioners choose different threshold values for the same medical indication and are influenced by their individual judgement and experience. In medical practice, a further medical treatment is arranged by the medical practitioner based on the concentration of the biomarker determined by the laboratory. This results in, for example, that the medical practitioner has to decide whether the administration of a certain treatment is sufficient or whether other medical treatments have to be initiated. The decision on how the patients are divided into risk groups is taken by the medical practitioner: For example he could divide the patients into three different categories based on the risk: High-risk patients, and low-risk patients. The medical practitioner then sets, for example, a threshold value, which is based on the percentile of the statistical calculations. However, he could also define several risk groups of the patients and set two or three threshold values, e.g. to distinguish high, medium and low risk groups.

Present examples 9 and 11 show that within the group of patients with cardiogenic shock and septic shock, respectively, patients with DPP3 levels in the 3rd quartile have a significantly higher occurrence of refractory shock than patients with lower DPP3 levels (also see Figs. 13 and 15). The absolute cutoffs are 59.1 ng/ml in the cardiogenic shock patients and 48.4 ng/mL in septic shock patients respectively.

Moreover, a medical practitioner may choose the threshold depending on whether more false-positive or false-negative results are considered tolerable. The medical practitioner will initiate medical treatment based on the division of

the patients into the respective risk group. This leads to the conclusion that the specific value of a threshold value can vary for good reasons.

It is also emphasized that fixing the threshold to an absolute number would unduly restrict the scope of the claims, which could then be easily circumvented. A suspected infringer could, by choosing a slightly different threshold, draw similar conclusions regarding the number of false positives or false negatives and thus circumvent the present invention. The applicant therefore kindly argues that the term “predetermined threshold” is sufficiently clear for the medical practitioner as a specialist to use the present invention and his experience to choose a suitable threshold and initiate appropriate treatment.

Finally, it is a principle well established by case law that claims must be clear for the sake of legal certainty, as their purpose is to enable the protection conferred by the patent to be determined. In the case of the present claims, the skilled person can determine the protection conferred by claim 1 without undue burden. Incidentally, it has also been accepted in a number of similar patents that the threshold need not be defined to have a specific value. Please, see in this regard e.g. granted patents EP2943792, EP2976646 and EP2823316. These are a small selection of granted patents where the language like “... wherein a level above a threshold is ...” has been accepted by the EPO without demanding the limitation of such a claim to a specific threshold which would make the scope of protection worthless. There is no apparent reason to decide otherwise in the present case.

- 2) The terms “inhibitors of the DPP3 activity” or “inhibitor of the activity of DPP3” were considered not clear.

Applicant respectfully disagrees. According to long-standing case law of the Boards of Appeal, the claims are to be interpreted from the viewpoint of the skilled person, who reads the claims with the mind willing to understand, not a mind desirous of misunderstanding (see e.g. section 6.1 of the present issue of the case law of the Boards of Appeal).

It is clear in view of the terms plain meaning, and in particular in view of the application as filed (see e.g. the description of activity measurement of DPP3 and determination of how said activity is inhibited by inhibitors under the present invention) that “DPP3 activity” or “activity of DPP3” refers to the enzymatic activity, not to a known or (partially) unknown physiological role, as seems to be insinuated by the Examining Division.

The skilled person also knows how to determine said activity and its inhibition, and is provided with additional information in the present application.

The term is therefore clear in the meaning of Article 84 EPC.

- 3) The objection over previous claims 13 and 18 is moot in view of their deletion.
- 4) In section 2.4 of the official communication, it is objected that it is not clear which compounds fall within the scope of the term "precursor of Angiotensin receptor agonists" in previous claims 15-16 and 18.

Corresponding present claims 14 and 15 have been amended as detailed above to further define the "precursor of Angiotensin receptor agonists", thus overcoming the objection.

The objection over previous claim 18 is moot in view of its deletion.

III. Novelty

The objection brought forward in item 3.5 of the Office Action, and Item 3 of the Office Action dated 20.11.2023 respectively, is moot in view of the deletion of claim 13.

Thus, the claimed subject matter is new.

IV. Inventive Step

D2 is considered as closest prior art.

While D2 shows that DPP3 is elevated in septic shock, there is no indication regarding refractory shock. Thus, the technical feature distinguishing the present invention from D2 is predicting or diagnosing specifically refractory shock with DPP3, or treating the same with a DPP3 inhibitor.

Even if a certain biomarker is known to be elevated in shock, this is no indication that said biomarker can differentiate between refractory and non-refractory shock within a certain shock group.

For instance, present examples 9 and 11 demonstrate that within the group of patients with cardiogenic shock and septic shock, respectively, patients with DPP3 levels in the 3rd quartile have a significantly higher occurrence of refractory shock than patients with lower DPP3 levels (also see Figs. 13 and 15).

None of the cited prior art documents disclose the connection between DPP3 and refractory shock. The present invention demonstrates for the first time that DPP3 is higher in patients with refractory shock than in shock patients without refractory shock and demonstrates the correlation with organ failure. This was simply not foreseeable from the prior art.

Thus, even if the skilled person would not arrive at the solution provided by claim 1 from the teaching of any of the cited prior art documents taken alone or in combination, which is therefore based on an inventive step.

The same considerations apply *mutatis mutandis* to claims 14 and 18, which are therefore likewise based on an inventive step.

V. Conclusion

In view of the amendments made and the above explanations, it is believed that the application is now in a state acceptable for grant. Should the Examining Division, nevertheless, still see deficiencies in the documents on file, it is kindly asked to give the applicant the opportunity to file further arguments and, if necessary, amendments. Minor issues could be discussed by telephone.

Only as a measure of precaution,

Oral Proceedings

are herewith requested.

BOEHMERT & BOEHMERT


Dr. Ute Kilger
Patent Attorney

Enclosures:

- New claims 1 to 18 (clean copy)
- New claims 1 to 18 (marked-up copy)